Gocovri is an anti-Parkinson's disease drug owned by Adamas Pharma. It contains the active ingredient amantadine hydrochloride and was first authorized for market use on August 24, 2017. With a total of 18 drug patents, none of them have expired yet. The drug is available in capsule, extended release; oral dosage forms.
The generics of Gocovri are expected to be released after August 23, 2038. This release date takes into account the expiry dates of the last patents held for the drug.
Gocovri is used in the treatment of dyskinesia in patients with Parkinson's disease receiving immediate release levodopa-based therapy, with or without concomitant dopaminergic medications. It can be used for decreasing 'off time' and increasing 'on time' without troublesome dyskinesia, offering patients with Parkinson's much-needed relief.
Gocovri holds a total of 18 patents, the last of which is expected to expire on August 23, 2038. For anyone interested in when Gocovri generic drugs will enter the market, this date is a key reference point. Below are the details of the patents: